Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.

@article{Karbach2010TumorreactiveCT,
  title={Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.},
  author={Julia Karbach and Sacha Gnjatic and Armin Bender and Antje B. Neumann and Eckhart Weidmann and Jianda Yuan and Cathy A. Ferrara and Eric Hoffmann and L. John Old and Nasser Khaled Altorki and E. P. Jaeger},
  journal={International journal of cancer},
  year={2010},
  volume={126 4},
  pages={909-18}
}
Peptide-based vaccines have led to the induction of antigen-specific CD8(+) T-cell responses in patients with NY-ESO-1 positive cancers. However, vaccine-induced T-cell responses did not generally correlate with improved survival. Therefore, we tested whether a synthetic CpG 7909 ODN (deoxycytidyl-deoxyguanosin oligodeoxy-nucleotides) mixed with NY-ESO-1 peptide p157-165 and incomplete Freund's adjuvants (Montanide(R) ISA-51) led to enhanced NY-ESO-1 antigen-specific CD8(+) immune responses in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…